**Abstracts**

**IGCS19-0136**

**WOMEN'S SEXUALITY POST GYNAECOLOGICAL CANCER TREATMENT AT GROOTE SCHUUR HOSPITAL: A QUALITATIVE, DESCRIPTIVE STUDY USING A COMPREHENSIVE FRAMEWORK**

S Pitcher, N Fakie, T Adams*, L van Wijk, R Saidu, L Denny, J Moodley. UCTSAMRC Gynaecological Cancer Research Centre, Obstetrics and Gynaecology, Cape Town, South Africa

10.1136/ijgc-2019-IGCS.387

**Objectives** This study aimed to investigate women’s experiences of their sexuality post gynaecological cancer treatment by using a comprehensive framework of sexuality, and, to understand how their sexual health needs can be best addressed as part of cancer care.

**Methods** The study made use of a qualitative descriptive design. Participants were recruited through purposive sampling at follow-up clinics within Groote Schuur Hospital’s Gynaecology Oncology Unit. The final sample consisted of 35 women aged 29–35. All women had been diagnosed with one or more gynaecological cancer and treated with either surgery, chemotherapy, radiation or a combination of these. Data was collected using semi-structured, in-depth individual interviews in participants’ home language. Pile sorting was used within the interviews to facilitate discussion about difficult topics. The data was analysed using thematic analysis.

**Results** The results are expected to provide thorough insight into women’s sexual functioning and psycho-sexual well-being post treatment and how this affects their lives and relationships.

**Conclusions** Such information can help develop support programs to improve patients’ quality of life post treatment. Furthermore, this research expands the qualitative literature relating to gynaecological cancers in South Africa.

**Trials in Progress**

**IGCS19-0755**

**SHORT-COURSE HIPEC AT THE TIME OF INTERVAL DEBULKING SURGERY FOR HIGH TUMOR BURDEN OVARIAN CANCER: PRELIMINARY RESULTS OF A PIONEERING CLINICAL TRIAL IN BRAZIL**

J Di Guilmi*, MC Darin, I Monjo, M Garcia Zeman, GA Maya. Hospital Britanico de Buenos Aires, Gynecology Oncology, Buenos Aires, Argentina

10.1136/ijgc-2019-IGCS.389

**Objectives** To report initial experience in Argentina using a local production ICG. Evaluating detection rates, incidence of nodal metastasis and adverse effects.

**Methods** Prospective non randomized single centre study that included patients with endometrial and cervical cancer (Surgical stages). The protocol and the inform consent were included patients with endometrial and cervical cancer (Surgical stages). The protocol and the inform consent were approved by ANMAT (National Administrations of Drugs, Food an Technology) for use in this protocol. Karl Storz Image 1 S laparoscopic system was used and the technique was standardized by protocol.

**Results** 51 patients were included between july 2017-march 2019. 18 had low risk endometrial carcinoma and 17 high risk. in the 1st group we only performed SLN biopsy. In the high-risk group, we performed SNL plus lymphadenectomy. 16 patients had cervical cancer. At least one SLN was found in 98% (50/51) for ICG. Bilateral detection rate was 88%

**IGCS19-0447**

**SENTINEL NODE MAPPING WITH INDOCYANINE GREEN (ICG): INITIAL ANALYSIS OF PROSPECTIVE STUDY**

J Di Guilmi*, MC Darin, I Monjo, M Garcia Zeman, GA Maya. Hospital Britanico de Buenos Aires, Gynecology Oncology, Buenos Aires, Argentina

10.1136/ijgc-2019-IGCS.389

**Objectives** To present the postoperative outcomes in our ongoing clinical trial.

**Methods** Cross-sectional analysis of early data from our phase 2 trial – an open-label, multicenter, single-arm trial on the safety and efficacy of neoadjuvant chemotherapy (NACT) followed by fast-track cytoreductive surgery (CRS) plus short-course HIPEC in advanced ovarian cancer (ClinicalTrials.gov: NCT02249013).

**Results** Fifteen patients with stage IIIb (n=1) or IIIC (n=14) epithelial malignancies were enrolled until July, 2019. The median (range) age was 46 years (19–67), with preoperative serum CA125 levels of 737.7U/mL (161.6–6550). The median number of NACT cycles was 3 (2–4), resulting in PFI scores of 11 (3–18) at the time of CRS/Hipec – after a post 26 (26–43) from the last NACT cycle. Time to restart i.v. chemotherapy was 39 days (31–74). Median operation time was 490 minutes (235–865), with 9 patients requiring major bowel resection as rectosigmoidectomy (n=8) or partial colectomy (n=1). Median length of hospital stay was 5 days (3–10), with ICU stay of 1 day (1–5). Four patients experienced no postoperative complications, whereas 5 suffered only minor G1/G2 complications, and 6 suffered major G3 complications, according to the NCI/CTCAE classification. The most common complications were electrolytes imbalance and anemia. Two patients experienced reoperation because of G3 postoperative hemorrhage or peritoneal infection, whereas no deaths were recorded.

**Conclusions** Our protocol seems to be feasible and safe, with manageable low rates of short- and middle-term complications. Recruitment to this pioneering clinical trial in Brazil is ongoing.